| Jun 3 |
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
|
| Jun 3 |
Heard on the Street: Wall Street Is Cheering a New Obesity Pill Candidate. Here's Why.
|
| Jun 3 |
Structure Therapeutics Stock Soars on Obesity Pill Data
|
| Jun 3 |
Structure Therapeutics rises after obesity treatment study meets main and secondary goals
|
| Jun 3 |
Structure pill leads to competitive weight loss in obesity study
|
| Jun 3 |
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
|
| Jun 2 |
SA Asks: Which weight-loss stocks should investors be watching?
|
| Jun 2 |
J.P. Morgan Predicts up to 210% Gains for These 2 ‘Strong Buy’ Stocks
|
| May 22 |
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
|
| May 21 |
J.P. Morgan starts Structure at overweight, cites GLP-1 drug candidate
|
